SCHEMBL463549

SCHEMBL463549

CCCCCCOC1(C(=O)O)CC=CC=C1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 1/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
PLA2G4B P0C869 5/20 0.38
RARB P10826 3/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PLA2G4A P47712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27626499 0.70 PLA2G2A (0.35) PLA2G2ATP53TSHRPLA2G4BRARB
SCHEMBL9272470 0.69 TP53 (0.33) PLA2G2ATP53TSHRPLA2G4BMEN1
SCHEMBL8868294 0.64 THRA (0.33) PLA2G2ATP53TSHRPLA2G4BMEN1
SCHEMBL28434026 0.62 MEN1 (0.45) TP53TSHRPLA2G4BRARBMEN1
SCHEMBL8532373 0.61 CYP4F2 (0.44) TSHRMEN1KMT2A
SCHEMBL22335910 0.61 CYP4F2 (0.46) TSHRMEN1KMT2ATDP1
SCHEMBL16429168 0.59 PLA2G2A (0.56) PLA2G2ATP53TSHRPLA2G4BRARB
SCHEMBL10537637 0.59 PLA2G2A (0.56) PLA2G2ATP53TSHRPLA2G4BRARB
SCHEMBL9863290 0.59 ALDH1A1 (0.57) TP53TSHR
SCHEMBL5646162 0.59 GPR84 (0.36) TSHRMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11623022-B2 Systems and methods for reconstruction of nerve defects University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2023-04-11 US disclosed
US-11147904-B2 Implantable medical devices having double walled microspheres University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2021-10-19 US disclosed
EP-3435988-B1 DRUG-CONTAINING PARTICULATE COMPOSITION WITH CATIONIC AGENT, ASSOCIATED MEDICAL DEVICES, AND METHODS FOR TREATMENT SURMODICS INC (US) 2021-10-06 EP disclosed
US-11123459-B2 Hydrophobic active agent particle coatings and methods for treatment SURMODICS, INC. (US) 2021-09-21 US disclosed
US-20210220866-A1 COATING SYSTEMS FOR MEDICAL DEVICES BANK OF MONTREAL, AS COLLATERAL AGENT 2021-07-22 US disclosed
US-11020513-B2 Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery SURMODICS, INC. (US) 2021-06-01 US disclosed
US-20200368390-A1 SYSTEMS AND METHODS FOR RECONSTRUCTION OF NERVE DEFECTS UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2020-11-26 US disclosed
EP-3554571-A1 HYDROPHOBIC ACTIVE AGENT PARTICLE COATINGS AND METHODS FOR TREATMENT Surmodics, Inc. (US) 2019-10-23 EP disclosed
EP-2689789-B1 Insertable medical devices having microparticulate-associated elastic substrates and methods for drug delivery SURMODICS INC (US) 2019-03-13 EP disclosed
EP-3436097-A1 LOCALIZED TREATMENT OF TISSUES THROUGH TRANSCATHETER DELIVERY OF ACTIVE AGENTS Surmodics, Inc. (US) 2019-02-06 EP disclosed
US-20080020045-A1 Combination Degradable and Non-Degradable Matrices for Active Agent Delivery BANK OF MONTREAL, AS COLLATERAL AGENT 2008-01-24 US disclosed
WO-2008008253-A2 IMPLANTABLE MEDICAL ARTICLES HAVING PRO-HEALING COATINGS SURMODICS, INC. (US) 2008-01-17 WO disclosed
WO-2008003043-A2 COMBINATION DEGRADABLE AND NON-DEGRADABLE MATRICES FOR ACTIVE AGENT DELIVERY SURMODICS, INC. (US) 2008-01-03 WO disclosed
US-20070275027-A1 Microparticle containing matrices for drug delivery BANK OF MONTREAL, AS COLLATERAL AGENT 2007-11-29 US disclosed
WO-2007109069-A2 HYDROPHOBIC DERIVATIVES OF NATURAL BIODEGRADABLE POLYSACCHARIDES AND USES THEREOF SURMODICS, INC. (US) 2007-09-27 WO disclosed
US-20070224247-A1 Biodegradable hydrophobic polysaccharide-based drug delivery implants SURMODICS MD, LLC 2007-09-27 US disclosed
US-20070218102-A1 Biodegradable hydrophobic polysaccharide-based coatings SURMODICS, INC. 2007-09-20 US disclosed
WO-2007084418-A2 MICROPARTICLE CONTAINING MATRICES FOR DRUG DELIVERY SURMODICS, INC. (US) 2007-07-26 WO disclosed
US-20070128343-A1 Apparatus And Methods for Applying Coatings BANK OF MONTREAL, AS COLLATERAL AGENT 2007-06-07 US disclosed
WO-2007059144-A1 ULTRASONIC NOZZLES FOR APPLYING TWO-COMPONENT COATINGS SURMODICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080020045-A1 Combination Degradable and Non-Degradable Matrices for Active Agent Delivery MMP1, MMP26, MMP24 PLA2G2A 925/4885TP53 2173/4885TSHR 4384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.